Motor features and response to oral levodopa in patients with Parkinson’s disease under continuous dopaminergic infusion or deep brain stimulation

Background:  Subthalamic nucleus deep brain stimulation (STN DBS) and continuous dopaminergic infusions (jejunal levodopa or subcutaneous apomorphine) are indicated in complicated Parkinson’s disease (PD), although it remains unsettled how they compare to each other.

[1]  Angelo Antonini,et al.  A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation , 2011, Journal of Neurology.

[2]  A. Albanese,et al.  Dopaminergic therapy and subthalamic stimulation in Parkinson’s disease: a review of 5-year reports , 2010, Journal of Neurology.

[3]  Alfredo Berardelli,et al.  Late (Complicated) Parkinson's Disease , 2010 .

[4]  A. Bentivoglio,et al.  Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants. , 2010, Brain : a journal of neurology.

[5]  Keith Wheatley,et al.  Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial , 2010, The Lancet Neurology.

[6]  Victor Sanchez,et al.  A Randomized Trial of Deep-Brain Stimulation for Parkinson's Disease , 2010 .

[7]  D. Devos.  Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[8]  D. Nyholm,et al.  Comparison of apomorphine and levodopa infusions in four patients with Parkinson’s disease with symptom fluctuations , 2009, Acta neurologica Scandinavica.

[9]  A. Bentivoglio,et al.  Replacement of dopaminergic medication with subthalamic nucleus stimulation in Parkinson's disease: Long‐term observation , 2009, Movement disorders : official journal of the Movement Disorder Society.

[10]  P. A. House,et al.  Bilateral Deep Brain Stimulation vs Best Medical Therapy for Patients With Advanced Parkinson Disease: A Randomized Controlled Trial , 2009 .

[11]  A. Albanese,et al.  Levodopa-induced dyskinesias and their management , 2008, Journal of Neurology.

[12]  Pablo Mir,et al.  Efficacy of long‐term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study , 2008, Movement disorders : official journal of the Movement Disorder Society.

[13]  Gilberto Fisone,et al.  Parkinson's disease: Levodopa‐induced dyskinesia and signal transduction , 2008, The FEBS journal.

[14]  A. Hsu,et al.  The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease. , 2007, Current clinical pharmacology.

[15]  L. Lopiano,et al.  Duodenal levodopa infusion for advanced Parkinson's disease: 12‐month treatment outcome , 2007, Movement disorders : official journal of the Movement Disorder Society.

[16]  G. Deuschl,et al.  A randomized trial of deep-brain stimulation for Parkinson's disease. , 2006, The New England journal of medicine.

[17]  G. Deuschl,et al.  Subthalamic nucleus deep brain stimulation: Summary and meta‐analysis of outcomes , 2006, Movement disorders : official journal of the Movement Disorder Society.

[18]  K. Østergaard,et al.  Evolution of Parkinson's disease during 4 years of bilateral deep brain stimulation of the subthalamic nucleus , 2006, Movement disorders : official journal of the Movement Disorder Society.

[19]  C. Mariani,et al.  Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson’s disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[20]  Laurent Gerbaud,et al.  Impact of the motor complications of Parkinson's disease on the quality of life , 2005, Movement disorders : official journal of the Movement Disorder Society.

[21]  Andrew Evans,et al.  Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single‐dose challenges , 2005, Movement disorders : official journal of the Movement Disorder Society.

[22]  D. Nyholm,et al.  Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease , 2005, Neurology.

[23]  A. Berardelli,et al.  Apomorphine Infusion and the Long-Duration Response to Levodopa in Advanced Parkinson's Disease , 2003, Clinical neuropharmacology.

[24]  V. Laulumaa,et al.  Economic burden and quality of life impairment increase with severity of PD. , 2003, Parkinsonism & related disorders.

[25]  Andrew J Lees,et al.  Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long‐term follow‐up study of 64 patients , 2002, Movement disorders : official journal of the Movement Disorder Society.

[26]  A. Benabid,et al.  The impact on Parkinson’s disease of electrical parameter settings in STN stimulation , 2002, Neurology.

[27]  P. Krack,et al.  Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. , 2001, The New England journal of medicine.

[28]  A. Benabid,et al.  Improvement of levodopa induced dyskinesias by thalamic deep brain stimulation is related to slight variation in electrode placement: possible involvement of the centre median and parafascicularis complex , 1999, Journal of neurology, neurosurgery, and psychiatry.

[29]  P. Remy,et al.  Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT‐PD) , 1999, Movement disorders : official journal of the Movement Disorder Society.

[30]  M. Contin,et al.  Pharmacokinetic Optimisation in the Treatment of Parkinson’s Disease , 1996, Clinical pharmacokinetics.

[31]  B. Långström,et al.  Levodopa‐induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET , 1996, Neurology.

[32]  R. Djaldetti,et al.  Gastric emptying in Parkinson's disease , 1996, Neurology.

[33]  J. Langston,et al.  Double‐blind, placebo‐controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on‐off' fluctuations , 1993, Neurology.

[34]  J. Bennett,et al.  Suppression of dyskinesias in advanced Parkinson's disease , 1993, Neurology.

[35]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[36]  E. Montgomery.  Pharmacokinetics and pharmacodynamics of levodopa , 1992, Neurology.

[37]  S. Fahn.  Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .